While Th17 and Th22 cells directly promote tumor progression through the release of tumor-promoting cytokines such as IL-17A or IL-17, Tregs suppress the anti-tumor effector response of Th1 cells and cytotoxic CD8 T cells. This evidence concerns the gene IL17A and neoplasm.